18F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: A prospective validation of long-term outcomes

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 5, 2013, Pages 657-667

  Calvo, Felipe A ^a,b   Sole, Claudio V ^a,b,c   De La Mata, Dolores ^a   Cabezón, Luis ^a   Gómez Espí, Marina ^a   Alvarez, Emilio ^a,b   Madariaga, Paz ^d   Carreras, José L ^b,d,e  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c Instituto de Radiomedicina Santiago   (Chile)

^d Clinica La Luz   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

FDG PET; Locally advanced rectal cancer; Long term outcome; Neoadjuvant chemoradiotherapy; Response assessment

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; ELECTRON THERAPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTRAOPERATIVE RADIOTHERAPY; LOCALLY ADVANCED RECTAL CANCER; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; RECTUM CANCER; TREATMENT RESPONSE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECTUM TUMOR; REPRODUCIBILITY; SCINTISCANNING; TIME; TREATMENT OUTCOME; DIAGNOSTIC USE; RECTAL NEOPLASMS;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84891681054     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2341-y     Document Type: Article

References (36)

1. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1:1479-82.
2. Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol. 2008;47:20-31.
3. Nagtegaal ID, van Krieken JH. The role of pathologists in the quality control of diagnosis and treatment of rectal cancer - an overview. Eur J Cancer. 2002;38:964-72.
4. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic- Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-23.
5. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575-82.
6. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Pude?ko M, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72:15-24.
7. Blomqvist L, Glimelius B. The " good" , the " bad" , and the " ugly" rectal cancers. Acta Oncol. 2008;47:5-8.
8. Shields AF. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol. 2006;8:141-50.
9. Ichiya Y, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, et al. Assessment of response to cancer therapy using fluorine- 18 fluorodeoxyglucose and positron emission tomography. J Nucl Med. 1991;32:1655-60.
10. Capirci C, Rampin L, Erba PA, Galeotti F, Crepaldi G, Banti E, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging. 2007;34:1583-93.
11. Vliegen RF, Beets-Tan RG, Vanhauten B, Driessen A, Oellers M, Kessels AG, et al. Can an FDGPET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer? Strahlenther Onkol. 2008;184:457-64.
12. Janssen MH, Öllers MC, van Stiphout RG, Riedl RG, van den Bogaard J, Buijsen J, et al. PET-based treatment response evaluation in rectal cancer prediction and validation. Int J Radiat Oncol Biol Phys. 2012;82:871-6.
13. 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol. 2006;187:W202-8.
14. 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med. 2006;47:14-22.
15. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2004;58:528-35.
16. 18F-FDG PET biometabolic monitoring of neoadjuvant therapy effects in rectal cancer: focus on nodal disease characteristics. Radiother Oncol. 2010;97:212-6.
17. Calvo FA, Serrano FJ, Diaz-González JA, Gomez-Espi M, Lozano E, Garcia R, et al. Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation. Ann Oncol. 2006;17:1103-10.
18. Calvo FA, Gomez-Espi M, Diaz-Gonzalez JA, Alvarado A, Cantalapiedra R, Marcos P, et al. Intraoperative presacral electron boost following preoperative chemoradiation in T3-4Nx rectal cancer: initial local effects and clinical outcome analysis. Radiother Oncol. 2002;62:201-6.
19. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumor spread and surgical excision. Lancet. 1986;2:996-9.
20. American Joint Committee on Cancer. General information on cancer staging and end-results reporting. In: Cancer Staging Handbook. Seventh edition, Heidelberg: Springer; 2007. p. 1-39.
21. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-96.
22. Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P, et al. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med. 2003;44:1044-50.
23. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519-27.
24. Gosens MJ, Dresen RC, Rutten HJ, Nieuwenhuijzen GA, van der Laak JA, Martijn H, et al. Preoperative radiochemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumours. Ann Oncol. 2008;19:2026-32.
25. Valentini V, van Stiphout R, Lammering G, Gambacorta MA, Barba MC, Bebenek M, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 2011;29:3163-72.
26. Glynne-Jones R, Hughes R. Critical appraisal of the 'wait and see' approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg. 2012;99:897-909.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
28. Rau B, Hunerbein M, Barth C, Wust P, Haensch W, Riess H, et al. Accuracy of endorectal ultrasound after preoperative radiochemotherapy in locally advanced rectal cancer. Surg Endosc. 1999;13:980-4.
29. Chen CC, Lee RC, Lin JK, Wang LW, Yang SH. How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy? Dis Colon Rectum. 2005;48:722-8.
30. 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med. 2009;50 Suppl 1:43S-54S.
31. Amthauer H, Denecke T, Rau B, Hildebrandt B, Hünerbein M, Ruf J, et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging. 2004;31:811-9.
32. Guillem JG, Moore HG, Akhurst T, Klimstra DS, Ruo L, Mazumdar M, et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg. 2004;199:1-7.
33. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med. 2006;47:1241-8.
34. Avallone A, Aloj L, Caracò C, Delrio P, Pecori B, Tatangelo F, et al. Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging. 2012;39:1848-57
35. Janssen MH, Ollers MC, Riedl RG, van den Bogaard J, Buijsen J, van Stiphout RG, et al. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F- fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys. 2010;77:392-9.
36. Engenhart R, Kimmig BN, Strauss LG, Höver KH, Romahn J, Haberkorn U, et al. Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score. Strahlenther Onkol. 1992;168:203-12.